Investigating small cell lung cancer molecular status and heterogeneity utilising circulating tumour cells
Session type: Parallel sessions
Small Cell Lung Cancer (SCLC) is an aggressive, highly metastatic disease with dismal prognosis. Response rates to first line chemotherapy are high in most patients but progression free survival is short due to development of chemotherapy resistance via mechanisms not well understood. Serial biopsy in SCLC is challenging whereas the molecular analysis of circulating tumour cells (CTCs) offers a minimally invasive opportunity to study drug resistance mechanisms, evaluate CTC heterogeneity and reveal new drug targets.